Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing
AUTOR(ES)
LUCINDA, LEDA M.F., AARESTRUP, BEATRIZ J.V., REBOREDO, MAYCON M., PAINS, THAIS D.A., CHAVES, RAPHAEL Z., REIS, JOÃO E.P., LOUZADA, MÁRIO J.Q., GUERRA, MARTHA O.
FONTE
An. Acad. Bras. Ciênc.
DATA DE PUBLICAÇÃO
16/10/2017
RESUMO
ABSTRACT Evaluate the effect of the extract of Ginkgo biloba in the bone alkaline phosphatase, bone mineral density, in the mechanical properties of the tibia in rats with glucocorticoid-induced-osteoporosis. After osteoporosis induction, the rats were divided into five groups: Osteoporosis; EGb1 (28 mg/Kg); EGb2 (56 mg/Kg); alendronate (0.2 mg/animal) and control. The animals were treated during 20 and 30 days. The control group was compared with the osteoporosis’s (Student’s t-test), while the other were analyzed by ANOVA test followed by Tukey/Dunnett’T3 (p<0.05). In the osteoporosis group the bone alkaline phosphatase, bone mineral density, the bone stiffness, the maximum load and the resilience were reduced. The bone alkaline phosphatase values increased in the EGb1 and EGb2 groups (30 days). In addition, in the EGb2 and alendronate groups (20 and 30 days) the bone mineral density increased. The extract of Ginkgo biloba restored bone alkaline phosphatase and bone mineral density using dual-energy x-ray absorptiometry.
Documentos Relacionados
- Use of dual-energy x-ray absorptiometry in non-ruminant nutrition research
- Avaliação da composição corporal através Dual-energy X-ray absorptiometry (DEXA) em recém-nascidos de muito baixo peso : efeito do uso de fortificante do leite materno
- Dual-energy X-ray absorptiometry modeling to explain the increased resting energy expenditure associated with the HIV lipoatrophy syndrome1234
- Assessment of adiposity in psoriatic patients by dual energy X-ray absorptiometry compared to conventional methods
- An inconvenient status in anti-osteoporotic treatment process: corticosteroid use